Unit | Clinical Immunology

Our group focuses on systems-immunology-based approaches within the framework of Phase I to III clinical trials. We aim to identify surrogates of protection as well as host factors elicited by subunit and whole parasite vaccines against tuberculosis (TB) and malaria. Clinical trials are performed with our partners of the Ifakara Health Institute in Bagamoyo. Further, the unit develops novel diagnostic tools for paediatric clinical TB in high endemic countries.


Co-morbidity studies analyse the impact of non-communicable diseases on immune responses against infectious diseases, particularly TB. Unit researchers also work to understand the consequences of helminth co-infections on malaria, TB and HIV pathogenesis and immunity.

Billingsley P.F et al. The equatoguinean malaria vaccine initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa. Am J Trop Med Hyg. 2020(in press). DOI: 10.4269/ajtmh.19-0966

Camponovo F et al. Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults. Elife. 2020;9:e53080. DOI: 10.7554/eLife.53080

Daubenberger C.A. Towards protective immune responses against malaria in pregnant women. Lancet Infect Dis. 2020;20(5):517-519. DOI: 10.1016/S1473-3099(20)30002-5

Geiger K.M et al. Epitope mapping and fine specificity of human T and B cell responses for novel candidate blood-stage malaria vaccine P27A. Front Immunol. 2020;11:412. DOI: 10.3389/fimmu.2020.00412

Guirou E.A et al. Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests. Sci Rep. 2020;10:12305. DOI: 10.1101/2020.02.17.20023960